Boxer Capital’s Altimmune ALT Stock Holding History

Boxer Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$6.38M	–	73
2022 Q3	$6.38M	Buy	+500,000	New	+$7.38M	0.36%	48

Other funds holding ALT

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Boxer Capital's ALT Position: Q4 2022 in Review

Boxer Capital sold out of Altimmune (ALT) in Q4 2022, closing a stake of 500,000 shares — an estimated $6.38M sold.

Boxer Capital first reported a position in ALT in Q3 2022 and held it in 1 quarter. The position peaked at $6.38M in Q3 2022. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

Boxer Capital reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
Boxer Capital sold 500,000 Altimmune shares in Q4 2022, an estimated $6.38M.
Boxer Capital first reported a position in Altimmune in Q3 2022 and held it in 1 quarter.
Boxer Capital's Altimmune position peaked at $6.38M in Q3 2022.
128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on Boxer Capital's 13F filing for Q4 2022, filed 14 Feb 2023.